MGF (Mechano Growth Factor) Side Effects: What Studies Report

Searches for MGF safety information run into two problems at once: the peer-reviewed literature that uses the abbreviation "MGF" describes several unrelated subjects, and none of the verified papers below is a human tolerability or adverse-event trial of a mechano growth factor peptide. This page summarises what the published studies actually examined, what they reported, and where the record is silent. This page is for educational purposes only and is not medical advice; consult a licensed physician for any health decision.

What "MGF" Refers To in the Published Literature

In muscle and skeletal biology, MGF is shorthand for mechano growth factor, a splice variant of insulin-like growth factor 1 whose C-terminal sequence is often studied as a separate synthetic "E peptide." A 2018 paper in Cell Biochemistry and Function used exactly that framing, examining MGF E peptide in bone marrow stromal cells under severe hypoxia (PMID 29441602).

The same three letters, however, carry different meanings elsewhere. In African swine fever virus research, MGF denotes viral multigene families; a 2023 study in Vaccines investigated the involvement of the MGF 110-11L gene in African swine fever virus replication and virulence (PMID 37112759). In natural-product chemistry, MGF has been used for mangiferin, as in a 2021 Scientific Reports paper on green nanotechnology of MGF-AuNPs for immunomodulatory intervention in prostate cancer therapy (PMID 34408231). Readers comparing "MGF safety" claims should first establish which MGF a given paper studied, because the subjects share nothing but an acronym.

Human Safety Data on MGF Peptide: What Studies Report

Across the verified papers, there is no clinical trial, no phase I tolerability study, and no case series that administered a mechano growth factor peptide to human participants and recorded adverse events. That absence is the single most important finding on this page. It is not evidence of safety and it is not evidence of harm; it means no published human adverse-event profile exists to summarise, so the frequency, severity, dose-relationship and reversibility of any effect in people remain unreported in this evidence set.

Because no human dose has been published in the verified literature, no dose, schedule or exposure range is stated anywhere on this page. Where a number cannot be traced to a cited paper, it is omitted rather than paraphrased or estimated.

What that means when reading secondary claims

• Claims about "common side effects" of MGF in humans do not trace to the verified papers, none of which enrolled human participants for peptide administration.
• Claims that MGF is "well tolerated" also do not trace to the verified papers, because tolerability was not an endpoint in any of them.
• Mechanistic findings in isolated cells, such as the signalling results reported in bone marrow stromal cells under severe hypoxia (PMID 29441602), describe what happened in a dish and were not framed by the researchers as clinical safety outcomes.

Cell and Mechanistic Findings: What Studies Report

The clearest peptide-level work in this set is the 2018 study in which researchers reported that ERK1/2 and Akt phosphorylation were essential for MGF E peptide regulating cell morphology and mobility, but not the proangiogenic capacity, of bone marrow stromal cells under severe hypoxia (PMID 29441602). Two aspects of that design matter for anyone reading it as safety evidence. First, the model was cultured cells in a low-oxygen environment, not a living organism with circulation, clearance and immune surveillance. Second, the endpoints were cell shape, movement and vessel-forming capacity — biological readouts, not toxicity measures such as organ histology, blood chemistry or symptom reporting.

Pathways like ERK1/2 and Akt are widely shared across tissues, which is why researchers generally treat signalling-level activity as a reason for further study rather than as a conclusion about systemic risk. The study did not report organ-level or whole-animal outcomes, so questions about effects outside the cultured cell system were not addressed by it.

Delivery and Formulation Papers: What Studies Report

A 2013 paper in the Journal of Pharmaceutics described intranasal siRNA delivery to the brain using TAT/MGF-tagged PEGylated chitosan nanoparticles (PMID 26555995). Here the peptide sequence functioned as part of an engineered carrier system for a nucleic-acid cargo. The study's subject was therefore the delivery platform, and its findings should not be read as a tolerability assessment of a free peptide given on its own; carrier chemistry, route and cargo all differ.

Similarly, the 2021 Scientific Reports paper on MGF-AuNPs reported immunomodulatory intervention in prostate cancer therapy using gold nanoparticles produced by green nanotechnology (PMID 34408231). That work concerned a plant-derived compound bound to metal nanoparticles in an oncology model — a different entity and a different research question from mechano growth factor biology.

Why Virology "MGF" Safety Findings Do Not Transfer

A large share of PubMed hits for "MGF" belongs to African swine fever virus research, where the abbreviation labels viral gene families rather than a peptide. In that field, safety language does appear, but it applies to veterinary vaccines in pigs. Researchers reported safety and efficacy profiles of the live attenuated vaccine AVAC ASF LIVE for preventing African swine fever in pigs (PMID 40585856), and a separate 2022 study in Frontiers in Microbiology evaluated protection from a five-gene-deleted African swine fever virus vaccine candidate against homologous challenge (PMID 35966648). The same field also includes diagnostic work, such as a triplex qPCR assay developed to differentiate a highly virulent genotype I recombinant virus from low-virulence genotype I and genotype II African swine fever viruses circulating in China (PMID 40303009).

None of that literature speaks to a human peptide. It is included here only because acronym collisions are a common source of misattributed "MGF safety data," and because the 2023 gene-function study makes the alternate usage explicit (PMID 37112759).

Adjacent Human Growth-Factor Research: What Studies Report

The closest human-subject paper in the verified set did not study MGF at all. A 2017 preliminary study in Annals of Dermatology examined the effects of a multi-growth-factors-containing cream on post-thyroidectomy scars (PMID 28566908). It is relevant only as an illustration that growth-factor-containing products have been tested in people in topical, dermatological contexts, with their own endpoints and their own formulations. The study did not administer mechano growth factor peptide systemically, and its results cannot be extended to that question.

Verified Evidence at a Glance

Open Questions the Literature Has Not Answered

Framed as gaps rather than warnings, the verified papers leave the following unaddressed for mechano growth factor peptide in humans:

1. Whether any systemic exposure produces measurable adverse events, since no human administration study appears in this set.
2. Pharmacokinetics in people — absorption, half-life, clearance — none of which was measured in the cell-based study (PMID 29441602).
3. Immunogenicity of a synthetic peptide sequence in humans, an endpoint absent from the delivery-platform work (PMID 26555995).
4. Long-term consequences of activating widely shared growth pathways, which the 2018 study examined only as short-term cell behaviour under hypoxia (PMID 29441602).
5. Interactions with medications or medical conditions, which none of the verified papers investigated.

Regulatory Context

Research peptides of this type are commonly labelled for research use only, meaning they are supplied for laboratory investigation and are not approved medicines. No approved human drug product corresponding to mechano growth factor peptide appears in the verified literature summarised here, and the papers above were laboratory, animal-health or dermatological studies rather than regulatory submissions. This is educational information about the research record, not legal or medical advice.

How to Read Any Future MGF Safety Claim

Three checks keep the record straight. First, identify the entity: a paper about viral multigene families (PMID 37112759) or about mangiferin nanoparticles (PMID 34408231) is not about a growth-factor peptide. Second, identify the model: cells in hypoxic culture (PMID 29441602), a nanoparticle delivery system (PMID 26555995) and pigs receiving a veterinary vaccine (PMID 40585856) answer different questions. Third, identify the endpoint: protection against viral challenge (PMID 35966648) or scar appearance after surgery (PMID 28566908) are not human peptide tolerability endpoints. Applied consistently, those checks show that the human adverse-event profile of MGF peptide has simply not been published in this evidence base.

References

• ERK1/2 and Akt phosphorylation were essential for MGF E peptide regulating cell morphology and mobility but not proangiogenic capacity of BMSCs under severe hypoxia (Cell Biochemistry and Function, 2018)
• Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles (Journal of Pharmaceutics, 2013)
• Green nanotechnology of MGF-AuNPs for immunomodulatory intervention in prostate cancer therapy (Scientific Reports, 2021)
• Involvement of the MGF 110-11L Gene in the African Swine Fever Replication and Virulence (Vaccines, 2023)
• Safety and Efficacy Profiles of the Live Attenuated Vaccine AVAC ASF LIVE for Preventing African Swine Fever in Pigs (Transboundary and Emerging Diseases, 2025)
• Protection Evaluation of a Five-Gene-Deleted African Swine Fever Virus Vaccine Candidate Against Homologous Challenge (Frontiers in Microbiology, 2022)
• Establishment of a Triplex qPCR Assay for Differentiating Highly Virulent Genotype I Recombinant Virus From Low-Virulence Genotype I and Genotype II African Swine Fever Viruses Circulating in China (Transboundary and Emerging Diseases, 2024)
• The Effects of Multi-Growth Factors-Containing Cream on Post-Thyroidectomy Scars: A Preliminary Study (Annals of Dermatology, 2017)